

**AMENDMENTS TO THE CLAIMS**

1. (Currently Amended) A method for treating persons suffering from acute or chronic degenerative conditions or diseases of the eye primary open angle glaucoma which comprises administering a pharmaceutically effective amount of a histone deacetylase inhibitor, wherein said histone deacetylase inhibitor is selected from the group consisting of suberoylanilide hydroxamic acid (SAHA), MS-275, oxamflatin, trichostatin A, depsipeptides, and suberic bishydroxamate (SBHA).

2. (Canceled)

3. (Withdrawn) The method of Claim 2 wherein the condition or disease is dry AMD.

4. (Canceled)